The fall MDMA Therapy Training cohort is now underway and includes 520 trainees in a 100-hour online program, running through December 18. So far this year we’ve granted $900,000 in 231 Health Equity Scholarships and increased racial diversity of program trainees immensely. The 2022 training dates will be announced on the MAPS PBC website and publicly very soon. The training team is looking at two online cohorts again in 2022, and also in-person training retreats which we are very excited and eager to return to offering. The in-person training retreats will be a week-long residential training retreat with about 60 trainees, plus an online course before and after. The MDMA Therapy Training Program is accepting applicants on a rolling basis. More information about the program, including application link for clinicians and counselors, email newsletter sign up, and more, can be found here.
The Supervisor Training Program has just completed its second round of training; the last round was run in 2019. Seventeen Phase 3 therapists learned more about the MAPS inner-directed modality and prepared to work as associate supervisors supporting therapists entering into clinical trials and practice. The Training and Supervision Department has begun to envision and plan for what supervision will look like in a post-approval world. MAPS PBC will be recruiting many more supervisor candidates to join the Supervisor Training Program in advance of potential approval to support new therapists entering practice in a scalable way.
A new cohort of adherence raters began training in the Adherence Rater Training in September 2021. Adherence raters are mental health professionals who review recordings of therapy sessions conducted as part of the MDMA-assisted therapy clinical trials sponsored by MAPS PBC and assess sessions for fidelity to the MDMA-assisted therapy treatment manual and protocol. Forty-two adherence rater trainees are participating in a 65-hour online training this fall/winter to support the work of reviewing session videos for adherence to a set of pre-defined adherence criteria and providing feedback on therapeutic quality and competence in MAPS-sponsored clinical trials.